Drug-induced liver injury (DILI) | The Icelandic Health Science Institute

Epidemiology, biomarkers and clinical aspects of DILI due to infliximab

Prospective-European-DILI network

This research group has a focus on quantitative risk of idiosyncratic DILI in patients taking potentially hepatotoxic drugs. Also risk factors and outcome of patients with drug-induced autoimmune hepatitis due to the widely used biological agent, infliximab. We are participating in the Prospective-European-DILI network (pro-Euro-DILI), a project supported by the European Union and has the aims to study the biomarkers that could be useful in defining the etiology of DILI and for the prognosis in patients with DILI.

Our Principal investigator: Einar S. Björnsson Professor and the Chief of Internal Medicine at the University of Iceland